337 related articles for article (PubMed ID: 24127691)
1. Rates and predictors of response to anti-viral treatment for hepatitis C virus in HIV/HCV co-infection in a nationwide study of 619 patients.
Ioannou GN; Scott JD; Yang Y; Green PK; Beste LA
Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1373-84. PubMed ID: 24127691
[TBL] [Abstract][Full Text] [Related]
2. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G
J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817
[TBL] [Abstract][Full Text] [Related]
3. OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.
Bruno R; Cariti G; Nasta P; Capetti A; Ravasio V; Galli M; Raise E; Palmieri G; Iannacone C; Puoti M
Liver Int; 2015 Jan; 35(1):120-9. PubMed ID: 25041136
[TBL] [Abstract][Full Text] [Related]
4. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
Myers RP; Benhamou Y; Bochet M; Thibault V; Mehri D; Poynard T
AIDS; 2004 Jan; 18(1):75-9. PubMed ID: 15090832
[TBL] [Abstract][Full Text] [Related]
5. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
6. [Differential response to pegylated interferon plus ribavirin combination therapy in chronic hepatitis C and HIV/HCV co-infected patients].
Liu B; Cai WP; Hu FY; Xu M; Lan Y; Tang XP
Zhonghua Gan Zang Bing Za Zhi; 2013 Nov; 21(11):829-33. PubMed ID: 24331692
[TBL] [Abstract][Full Text] [Related]
7. [Clinical efficacy of pegylated interferon in patients co-infected with HIV and HCV who failed standard interferon therapy].
Ke YC; Li LH; Hu FY; He Y; Lan Y; Chen XJ; Tang XP; Cai WP
Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):181-5. PubMed ID: 27095760
[TBL] [Abstract][Full Text] [Related]
8. Real life experience in treatment of HIV-1/HCV-coinfected patients with pegylated interferon alpha and ribavirin: predictors of SVR.
Bruno G; Fasano M; Saracino A; Volpe A; Bartolomeo N; Ladisa N; Maggi P; Monno L; Angarano G
New Microbiol; 2015 Jan; 38(1):21-7. PubMed ID: 25742144
[TBL] [Abstract][Full Text] [Related]
9. Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort.
Doyle JS; Deterding K; Grebely J; Wedemeyer H; Sacks-Davis R; Spelman T; Matthews G; Rice TM; Morris MD; McGovern BH; Kim AY; Bruneau J; Lloyd AR; Page K; Manns MP; Hellard ME; Dore GJ;
J Viral Hepat; 2015 Dec; 22(12):1020-32. PubMed ID: 26098993
[TBL] [Abstract][Full Text] [Related]
10. Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin.
Monje-Agudo P; Castro-Iglesias A; Rivero-Juárez A; Martínez-Marcos F; Ortega-González E; Real LM; Pernas B; Merchante N; Cid P; Macías J; Merino MD; Rivero A; Mena A; Neukam K; Pineda JA;
Eur J Clin Microbiol Infect Dis; 2015 Oct; 34(10):1929-36. PubMed ID: 26155784
[TBL] [Abstract][Full Text] [Related]
11. Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
Moreno L; Quereda C; Moreno A; Perez-Elías MJ; Antela A; Casado JL; Dronda F; Mateos ML; Bárcena R; Moreno S
AIDS; 2004 Jan; 18(1):67-73. PubMed ID: 15090831
[TBL] [Abstract][Full Text] [Related]
12. IL15 polymorphism is associated with advanced fibrosis, inflammation-related biomarkers and virological response in human immunodeficiency virus/hepatitis C virus coinfection.
Jiménez-Sousa MA; Berenguer J; Rallón N; Pineda-Tenor D; Aldamiz-Echevarria T; Soriano V; García-Álvarez M; Vazquez-Morón S; Restrepo C; Carrero A; Benito JM; Resino S
Liver Int; 2016 Sep; 36(9):1258-66. PubMed ID: 26836972
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.
Crespo M; Mira JA; Pineda JA; Van den Eynde E; Ríos-Villegas MJ; Collado A; Girón-González JA; López-Cortés LF; González-Serrano M; Rivero A; Merino D; Esteban JI
J Antimicrob Chemother; 2008 Oct; 62(4):793-6. PubMed ID: 18567911
[TBL] [Abstract][Full Text] [Related]
14. OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients.
Carosi G; Bruno R; Cariti G; Nasta P; Gulminetti R; Galli M; Angarano G; Verucchi G; Pontali E; Capetti A; Raise E; Ravasio V; Maida I; Iannacone C; Caputo A; Puoti M
Antivir Ther; 2014; 19(8):735-45. PubMed ID: 24583976
[TBL] [Abstract][Full Text] [Related]
15. A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin.
Selvapatt N; Habibi MS; Brown A
J Med Virol; 2015 Oct; 87(10):1716-21. PubMed ID: 25914248
[TBL] [Abstract][Full Text] [Related]
16. Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study.
Milazzo L; Caramma I; Mazzali C; Cesari M; Olivetti M; Galli M; Antinori S
J Antimicrob Chemother; 2010 Apr; 65(4):735-40. PubMed ID: 20118492
[TBL] [Abstract][Full Text] [Related]
17. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM;
J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748
[TBL] [Abstract][Full Text] [Related]
18. [Discussion on optimal duration of pegylated interferon α combined with ribavirin for chronic hepatitis C in HIV-infected patients].
Ke YC; Li LH; Hu FY; Lan Y; He YZ; Chen XJ; Tang XP; Cai WP; Lu RC; He Y; Li HQ
Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):282-287. PubMed ID: 29996340
[No Abstract] [Full Text] [Related]
19. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.
Aziz H; Raza A; Waheed Y; Gill U; Gill ML
Int J Infect Dis; 2012 Aug; 16(8):e597-602. PubMed ID: 22658873
[TBL] [Abstract][Full Text] [Related]
20. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
Cotte L; Braun J; Lascoux-Combe C; Vincent C; Valantin MA; Sogni P; Lacombe K; Neau D; Aumaitre H; Batisse D; de Truchis P; Gervais A; Michelet C; Morlat P; Vittecoq D; Rosa I; Bertucci I; Chevaliez S; Aboulker JP; Molina JM;
Clin Infect Dis; 2014 Dec; 59(12):1768-76. PubMed ID: 25139963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
